Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Oncology Center of Excellence

Oncology Center of Excellence

                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community Home
          About FDA
          FDA Organization
          Oncology Center of Excellence
          Advancing Oncology Decentralized TrialsOncology Center of Excellence Advancing Oncology Decentralized Trials
  
  					Modernizing Evidence Generation
	
    Share
    Post
    Linkedin

    Email
    Print**Background**

In 2020, the US Food and Drug Administration issued guidance for trial investigators on clinical trial conduct for the duration of the COVID-19 public health emergency. This guidance clarified that, where appropriate, FDA regulations can accommodate the adoption of methods to facilitate trial decentralization through the remote collection of trial data outside of a standard in-person clinical trial site. These methods include patient-centric trial flexibilities such as electronic informed consent, virtual clinic visits, delivery of investigational product to the home and obtaining laboratory or imaging assessments locally.

The FDA Oncology Center of Excellence (OCE) supports efforts to modernize clinical trials and evidence generation. COVID-19 provided a proof of concept for several decentralized trial modifications, and OCE is engaging with stakeholders to evaluate the benefits and challenges seen with decentralized trials in order to prioritize streamlined procedures to deploy in future prospectively designed cancer clinical trials

**Why is This Important?**

Decentralized Clinical Trials (DCT) hold promise to reduce patient and sponsor burden and increase accrual and retention of a more diverse trial population, a key goal for OCE programs including Project Equity and Project Silver.
	Evaluating the COVID-19 experience with remote assessments is important to develop best practices when deploying DCT modifications in future prospective DCT designs.**Ongoing Initiatives**

The Clinical Trials Transformation Initiative (CTTI) Collaboration

There is a lack of data as to which DCT modifications were used in registrational trials conducted during the COVID-19 pandemic that subsequently were submitted and led to FDA approval of a new oncology indication.
	FDA OCE has partnered with the Clinical Trials Transformation Initiative (CTTI) to conduct sponsor surveys to understand the prevalence of remote trial modifications for trials that provided evidence supporting the approval of supplemental or new drug or biologic applications for oncology indications.ASCO - Friends of Cancer Research Protocol Adherence and Fidelity Project

Currently there isn’t a quantitative or qualitative analysis of the impact of COVID-era protocol deviations on clinical trial data from multiple sponsors.
	Using a mixed methods approach (sponsor survey, interviews, and data meta-analysis), the project aims to describe and evaluate the impact of the COVID-19 pandemic on the types, frequency, and risk of protocol deviations documented in cancer treatment trials.
	FDA’s OCE is providing oncology regulatory perspective as a member of this working group.**FDA Guidance Document**

FDA Draft Guidance on Decentralized Clinical Trials for Drugs, Biological Products, and Devices (May 2023)
	FDA Guidance on Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency (August 2021)**Select Publications**

Flaherty KT, Doroshow JH, Galbraith S, Ribas A, Kluetz PG, Pazdur R, Theoret MR. Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective. Cancer Discov. 2021 Aug;11(8):1881-1885
	Rivera DR, Kluetz PG, Abdallah K, Agrawal S, Angus DC, Califf RM, Garrett-Mayer E, Hyer R, Lowy DR, Khleif SN. Clinical Evidence Generation During a Pandemic: Lessons Learned for Sustaining Progress. Cancer J. 2022 Mar-Apr 01;28(2):151-156
	Friends of Cancer Research White Paper. Applying Learnings from Covid-19 to Advance Clinical Trial Conduct. Friends of Cancer Research Annual Meeting 2022**For Further Information**

Office of Oncologic Diseases (OOD)
	OOD Divisions and Contact Information
	Information for Sponsors: Submissions to the Office of Oncologic Diseases (OOD)
	Real-Time Oncology Review Pilot Program
	Oncology Regulatory Affairs

                                                                                  Content current as of:
      05/02/2023Oncology Center of Excellence

          
                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop